They reported that the cBioPortal for Cancer Genomics shows that 46.7% (245 cases out of 525 eligible cases) of all the subtypes of breast cancer patients either had a low expression, including deletions, of one of the PP2A complex components or a high expression, including amplification, of the inhibitory regulatory subunits (the criteria were generally mutually exclusive, except for PPP2CB and the PPP2R2A which can occur simultaneously). This evidence concerns the gene PTPA and breast cancer.